Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers
This research is a 'Phase I' clinical trial, which means it's one of the first studies in people. It's designed to understand how a new medicine, CHF6001, behaves in the body when taken with a common antibiotic called erythromycin. Erythromycin is known to affect how some medicines are processed. The study will look closely at how CHF6001 is absorbed, how it's broken down, and how it leaves the body when erythromycin is also present. This is important to ensure new medicines are safe and work correctly when people take other medications. This study involves healthy volunteers to get a clear picture of this interaction without other health conditions affecting the results.
At a glance
What is this study about?
This study is a Phase I trial. In simple terms, this means it's one of the very first steps in testing a new medicine in people. The main goal here isn't to treat a disease, but to understand how a new medication, called CHF6001, interacts with the body. We're particularly interested in how another common medicine, erythromycin, might affect CHF6001.
Erythromycin is an antibiotic that doctors sometimes prescribe. It's also known to influence how some other medicines are processed in your body, specifically through something called the CYP3A4/5 system. This study will carefully examine if taking erythromycin at the same time as CHF6001 changes how much of CHF6001 gets into your bloodstream, how long it stays there, and how your body gets rid of it. Understanding these interactions is crucial for making sure that when CHF6001 potentially becomes available, it can be used safely and effectively, especially if patients are also taking other medicines.
By studying healthy volunteers, the researchers can get a very clear picture of how these two medicines interact, without other health conditions making the results harder to interpret. This information helps them decide the right dose and how to use CHF6001 in the future, if it proves to be a helpful treatment.
Key takeaways
- This study is testing how a new medicine, CHF6001, acts in the body.
- It specifically looks at how a common antibiotic, erythromycin, might affect CHF6001.
- The study involves healthy adult volunteers, aged 18 or older, men and women.
- It's a Phase I study, focusing on safety and how the medicine is absorbed and cleared.
- Your participation helps to understand how medicines interact safely.
Who may be eligible?
To take part in this study, you need to be an adult, aged 18 years or older. This study is open to both men and women.
Since this is an early-stage study looking at how medicines interact, it recruits healthy volunteers. This means that to be eligible, you generally need to be in good health. The aim is to understand how the medicines work without other health issues complicating the results.
Other specific medical criteria, which aren't listed here, would also determine if you are suitable. For example, you might need to have certain liver or kidney function, and not be taking other specific medications. Researchers check these things carefully to ensure your safety and that the study results are clear.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you considered by doctors to be in good health?
- Are you comfortable potentially taking two different medicines?
- Are you willing to attend multiple clinic visits and potentially stay overnight?
What does participation involve?
The detailed description of what taking part involves isn't provided here, but for a typical Phase I study like this, you would generally expect to have several visits to a clinic or hospital. These visits would likely include initial health checks, blood tests, and possibly other examinations to make sure you are healthy enough to participate.
You would receive both the new medicine, CHF6001, and the antibiotic, erythromycin, according to a specific schedule determined by the researchers. This might involve staying overnight at a clinic, especially when blood samples need to be taken frequently to measure how the medicines are moving through your body. There would also be follow-up appointments to monitor your health and any effects of the medicines. The total duration of your participation, including follow-up, can vary but Phase I studies often last from a few days to a few weeks.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is CHF6001?
CHF6001 is a new medicine that is being investigated. This study is trying to understand how it behaves in the human body.
What does 'Phase I' mean?
Phase I is the earliest stage of testing a new medicine in people. It focuses on how the medicine works in the body and its safety, not on treating a specific disease.
Why is erythromycin used in this study?
Erythromycin is a common antibiotic. We know it can affect how some medicines are processed by the body, so researchers want to see if it changes how CHF6001 works.
Will I get paid to take part?
Payment for participation is common in Phase I studies to compensate volunteers for their time and travel, though it’s not explicitly stated here. You should ask the study team about this.
Do I have to be sick to join?
No, this particular study is looking for healthy volunteers, meaning people who do not have any major ongoing health conditions.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.